Clinical trial
Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease
NCT00311532 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease
- Lead sponsor
- Eli Lilly and Company
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2006
- Completion date
- May 31, 2007
- Enrollment
- 200 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.